

### The 57th Nordic Coagulation Meeting 11-13.9.2024, Helsinki, Finland

### **Final Program**

For the Symposia please check the final program and timings from the Congress website.

Scientific sessions include a Keynote lecture and local scientific presentations

# Wednesday 11.9.2024

10:00	Registration opens
10:30	Opening ceremony
10:40	Symposium I: Embracing shared approach to personalized treatment Organized by Novo Nordisk Farma
	Jovan P. Antovic, (Stockholm, Sweden): Cardiovascular risk in aging patients with hemophilia
	Peter Kampmann, (Copenhagen, Denmark): Future Landscape in Hemophilia - No One-Size-Fits-All
	Hermann Eichler (Homburg, Germany): Need of Real-World Evidence in Hemophilia
11:40	Lunch at the exhibition area
12:30	Session 1: von Willebrand disease and primary hemostasis
	Keynote lecture - Jecko Thachil (Manchester, United Kingdom): Why may bleeding occur in von Willebrand disease?
13:00	Vuokko Nummi (HUCH, Finland): von Willebrand disease beyond hemostasis
13:15	Timea Szanto (HUCH, Finland): Role of platelets in primary hemostasis disorders

13:30	Coffee at the exhibition area
14:00	Symposium II: von Willebrand disease and hemophilia: Future outlook Organized by CSL Behring
	Riitta Lassila (Helsinki, Finland): von Willebrand disease, remaining challenges
	Jan Astermark (Malmö, Sweden): Gene therapy, overview and practical considerations
15:00	Session 2: Update of hemophilia
15:00	Kirmo Wartiovaara (HU, Finland): Path to gene therapy and next steps
15:20	Nancy El Beayni (Beirut, Lebanon, ISTH Reach the World Fellowship 2023 at HUCH): Role of rotational thromboelastometry in patients on new hemophilia therapies
15:35	Refreshment at the Exhibition area
15:50	Symposium III: Management of non - severe hemophilia: not stronger than the
	weakest link Organized by Bayer Oy
	Organized by <b>Bayer Oy</b> Ragnhild Måseide (Oslo, Norway): Pursuit for a better life – the MOHEM study -
	Organized by <b>Bayer Oy</b> Ragnhild Måseide (Oslo, Norway): Pursuit for a better life – the MOHEM study - Mohem 1
16.50	Organized by <b>Bayer Oy</b> Ragnhild Måseide (Oslo, Norway): Pursuit for a better life – the MOHEM study - Mohem 1  Malu Hestdalen, (Oslo, Norway): Mohem 2
16.50 17:50	Organized by <b>Bayer Oy</b> Ragnhild Måseide (Oslo, Norway): Pursuit for a better life – the MOHEM study - Mohem 1  Malu Hestdalen, (Oslo, Norway): Mohem 2  Pål Andre Holme, (Oslo, Norway): What Happens to the PWH in Real Life?
	Organized by <b>Bayer Oy</b> Ragnhild Måseide (Oslo, Norway): Pursuit for a better life – the MOHEM study - Mohem 1  Malu Hestdalen, (Oslo, Norway): Mohem 2  Pål Andre Holme, (Oslo, Norway): What Happens to the PWH in Real Life?  Scientific Poster session

# Thursday 12.9.2024

8:00	Registration opens
8:30	Session 3: Critical role of Laboratory in Coagulation Disorders
	Keynote Lecture - Andreas Hillarp (Malmö, Sweden): Benchmarks of interaction between laboratory and clinic
9:00	Leena Hiltunen (FIMLAB, Finland): 30 years of experience in coagulation laboratory
9:20	Paula Savola (HUS Diagnostic Center, Finland): Evidence-based iron deficiency diagnostics in anemia
9:35	Marika Pikta (North Estonia Medical Centre Foundation, Estonia): Laboratory monitoring of antithrombotic treatment - Estonian experience
9:50	Coffee at the Exhibition area

# 10:15 Symposium IV: Path towards hemophilia free mind Organized by Roche Cedric Hermans, (Brussels, Belgium): remote lecture Hemophilia free mind and perspectives on emicizumab management Timea Szanto (Helsinki, Finland): Non-factor products in the laboratory - clinical view 11:15 Session 4: Thrombo-inflammation Keynote Lecture - Jerrold Levy (Durham, NC, USA): Thrombo-inflammation - from bench to bedside 11:45 Annukka Jouppila (HU, Finland): Thrombo-inflammation and heparin proteoglycan mimetic 12:00-13:30 Lunch at the posters and exhibition area (Nordic Hemophilia Council meeting, members only) Session 4: Thrombo-inflammation continues 13:30 Tuukka Helin (HUS Diagnostic Center, Finland): Extracellular vesicles in COVID-19 13:45 Hanna Pitkänen (HUCH, Finland): From classic HIT to VITT 14:00 **Session 5: Thrombotic microangiopathy** Keynote Lecture: Karen Vanhoorelbeke (Kortrijk, Belgium): Implications of ADAMTS13 conformation in the pathogenesis of thrombotic thrombocytopenic purpura 14:30 Inkeri Lokki (HU, Finland): Complement activation and pregnancy complications 14:50 Coffee at the Exhibition area 15:15 Symposium V: Practical management of aTTP Organized by Sanofi Alexandros Arvanitakis, (Malmö, Sweden): The Hematologist's view Mikko Haapio, (HUCH, Finland): The Nephrologist's view 16:15 Scientific poster session 19:30 Dinner Friday 13.9.2024 8:30 Registration opens 9:00 Symposium VI: Empowering hemophilia and PNH patients towards normalisation

Organized by Sobi

Eira Poikonen (Helsinki, Finland): PNH – Real-world experience

Pratima Chowdary (London, United Kingdom): A new horizon in hemophilia A care

Jan Astermark (Malmö, Sweden): Emerging therapies and the path to normalized hemostasis

Pål Andre Holme (Oslo, Norway): Joint Health in Hemophilia: The role of normalized hemostasis

#### 10:00 Session 6: Severe thrombosis and risk factors

Keynote Lecture - Simon De Meyer (Kortrijk, Belgium): Ischemic stroke clot composition: towards thrombolysis beyond fibrinolysis Matti Kaksonen (HUCH, Finland): Venous thromboembolism in special cases Coffee at the Exhibition area

#### Session 6 continues

10:30

10:45

12:15	Symposium VII: Improving patient management in von Willebrand disease Organized by Takeda
12:00	Miika Koskinen (HU, Finland): Outpatient low-molecular weight heparin and COVID-19
11:45	Sanna Susila (HUCH, Finland): Hemostatic properties of whole blood
11:30	Lasse Myllylahti (HUCH, Finland): Ovarian cancer and coagulation biomarkers
11:15	Nora Mattila: (HUCH, Finland): Pancreatic adenocarcinoma and coagulation

Jan Astermark (Malmö, Sweden): Diagnosis of von Willebrand disease - genetic considerations and subtypes

Flora Peyvandi (Milan, Italy): Long-term outcomes for patients with Type 3 von Willebrand disease

Maria Bruzelius (Stockholm, Sweden): Treatment decisions and patient management, when to consider prophylactic treatment in von Willebrand patients

13:15 Scientific poster awards

13:30 NordCoag2025

Adjourn and lunch